Navigation Links
Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C
Date:11/5/2007

ed at least comparable efficacy and comparable safety vs. peginterferon alfa-2a (ITT analysis), with less impairment of quality of life on treatment and fewer lost days of work. The final Phase 2b results include the following SVR rates and other findings:

Albuferon 900-mcg Every Two Weeks (Albuferon 900 Q2w)

-- Based on an intention-to-treat (ITT) analysis, 58.5% of patients in the

Albuferon 900 Q2w treatment group achieved SVR, vs. 57.9% for

peginterferon alfa-2a administered every week.

-- In heavier patients (75 kg or heavier) who were treatment-adherent,

74.2% of those in the Albuferon 900 Q2w treatment group achieved SVR,

versus 53.3% for peginterferon alfa-2a.

-- Among all treatment-adherent patients in the Albuferon 900 Q2w

treatment group, 72.3% achieved SVR, versus 66.7% for peginterferon

alfa-2a.

-- Based on the SF-36 Health Survey, patients in the Albuferon 900 Q2w

treatment group reported less impairment of health-related quality of

life, compared with patients in the peginterferon alfa-2a treatment

group, as measured by both physical component and mental component SF-

36 summary measures at all time-points throughout the 48-week treatment

period.

-- Significantly fewer working patients in the Albuferon 900 Q2w treatment

group reported missing 7 days or more of work during the month prior to

their visits at Weeks 12 and 24, vs. the peginterferon alfa-2a group

(p<.05; Week 12: 4.2% for Albuferon 900 Q2w vs. 18.1% for

peginterferon alfa-2a; Week 24: 5.3% for Albuferon 900 Q2w, vs. 20.3%

for peginterferon alfa-2a).

-- The rate of discontinuations due to adverse events was 9.3% in the

Albuferon 900 Q2w treatment group, vs. 6.1% in the peginterferon alfa-

2a group. Adverse events observed were those typically expected with

interferon therapy. '/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... Nov. 28, 2014 /CNW Telbec/ - Ergoresearch Ltd « Ergoresearch ... of Mrs. Dominique Boudreau who will hold ... Mrs. Dominique Boudreau was acting as corporate ... similar duties for more than seven years for Laboratoire ... January 2013.  Mrs. Boudreau replaces Mr. Greco who was ...
(Date:11/28/2014)... Kan. , Nov. 28, 2014 Aratana ... company focused on the licensing or acquisition, development and ... other companion animals, today announced that it will present ... Conference, to be held December 2-3, 2014, at the ... . Steven St. Peter , ...
(Date:11/28/2014)... 28, 2014 Alimera Sciences, Inc. (NASDAQ: ... that specializes in the research, development and commercialization ... Securities Purchase Agreement with Deerfield Management and certain ... will issue shares of preferred stock to Deerfield ... million upon the satisfaction of certain closing conditions. ...
Breaking Medicine Technology:Ergoresearch announces the appointment of its new Vice Président Finance 2Ergoresearch announces the appointment of its new Vice Président Finance 3Aratana Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference 2Alimera Sciences Announces Agreement with Deerfield Management for $50.0 Million Financing 2Alimera Sciences Announces Agreement with Deerfield Management for $50.0 Million Financing 3
... 5, 2011 Mylan Inc. (Nasdaq: MYL ) today ... of the NASDAQ OMX Group Inc. (Nasdaq: NDAQ ), ... due 2012 from the Nasdaq Capital Market, on which the notes ... of trading on January 28, 2011. The notes will continue to ...
... and older falls every 2.3 seconds in the U.S., and according ... cause of fatal injury in this age group. They are ... for trauma.  The growing ranks of Americans 65 and older - ... 2050 - have inspired a new technology solution that allows the ...
Cached Medicine Technology:Mylan Announces Voluntary De-listing of 1.25% Senior Convertible Notes Due 2012 from Nasdaq 2SecuraTrac Reveals Revolutionary Safety Solution Based on GPS & Cellular Technology at CES 2011 2SecuraTrac Reveals Revolutionary Safety Solution Based on GPS & Cellular Technology at CES 2011 3
(Date:11/28/2014)... Miami's Plastic Surgery of the Face recently introduced ... Jeffrey Epstein is excited to offer patients the ... the site is uniquely designed for easing viewing on ... of all prospective rhinoplasty patients research upcoming procedures online. ... with smartphones, tablets, and laptops, as well as the ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 Written and narrated ... Brook Forest Voices releases the “The Happiest Man In ... a compelling account of how and why Project C.U.R.E. came ... by his mother Josie and the Reverend Richard W. Jackson, ... the age of 30, but realized that he wasn’t happy. ...
(Date:11/28/2014)... Not only is the Éminence Organic ... petroleum, parabens and other cancer-causing agents, but they are ... and awareness programs that help in the fight against ... raised an incredible, record-breaking contribution of $30,000 through participation ... the Sweet Red Rose Whip Moisturizer and the company’s ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 Mabel’s ... stuff kids lose® and an award-winning company established by ... Ellis, Cynthia Esp, and Tricia Mumby have been honored ... were recognized with the PROFIT Award for Excellence in ... Cynthia Esp, and Tricia Mumby) accepted the award on ...
(Date:11/28/2014)... Lice Troopers Lice Removal Service is pleased to ... lice service for moms in Miami-Dade County. Lice Troopers is ... on Pone De-leon Blvd in Miami. The company currently ... Miami-Dade & Broward. Lice Troopers is the only Lice Clinic ... been treating families for several years. , Lice Troopers estimate ...
Breaking Medicine News(10 mins):Health News:Top Rhinoplasty Surgeon Launches Innovative Website 2Health News:Thanksgiving Weekend Audiobook Treat! “The Happiest Man In the World: Life Lessons From a Cultural Economist” by Dr. James W. Jackson 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 3Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 2Health News:Mabel's Labels’ Co-Founders Named A Winner In The 2014 RBC Canadian Women Entrepreneur Awards Program; A Second-Time Win For The Brand 3Health News:Lice Troopers Lice Removal Service Expands in Miami-Dade 2
... ... for dentists with advanced clinical training announced. , ... Seattle, WA (PRWEB) June 23, 2009 -- Big Case Marketing, the global ... for large cases and Dental Idea Lab, a Boston based coaching and consulting firm for ...
... ... and FIND (Foundation for Innovative New Diagnostics), a Swiss foundation that develops, evaluates and ... price reduction in the cost of liquid culture testing for TB (Tuberculosis). , ... Oxford, UK and Geneva, ...
... SAN DIEGO, June 22 CetylMax, LLC and Flexadren, ... Cetylated Fatty Acids (CFA,s) products aiding in joint support ... Board: IAGX), the manufacturer of Celadrin, did not prevail ... the nature and outcome of the Federal litigation between ...
... inhibitor of tumor metastasis made by tumor cells, one that ... were published in the online Early Edition of the ... week of June 22. Metastasisthe migration of cancer ... leading causes of death from cancer, and there is no ...
... WASHINGTON, June 22 The Lupus Foundation of America ... studies on lupus, an unpredictable and potentially fatal autoimmune ... lupus and adult stem cell transplantation. The purposes of ... research in humans as a treatment for lupus and ...
... , , Personalized Medicine Meeting Elicits Varying Perspectives ... Drug Administration,s (FDA,s) ability to regulate genetic testing is problematic, ... , Three-quarters of the attendees at a colloquium ... Institute (FDLI) and the American Association for the Advancement of ...
Cached Medicine News:Health News:One of a Kind Marketing and Sales Summit for Dentists Announced 2Health News:One of a Kind Marketing and Sales Summit for Dentists Announced 3Health News:BD and FIND Achieve Milestone in Global Battle Against MDR-TB 2Health News:BD and FIND Achieve Milestone in Global Battle Against MDR-TB 3Health News:BD and FIND Achieve Milestone in Global Battle Against MDR-TB 4Health News:CetylMax(R) and Flexadren(R) Win Federal Lawsuit - Court Rules Against Imagenetix 2Health News:CetylMax(R) and Flexadren(R) Win Federal Lawsuit - Court Rules Against Imagenetix 3Health News:Potent metastasis inhibitor identified 2Health News:Lupus Foundation of America Seeks Proposals for Research Studies on Childhood Lupus and Stem Cell Transplantation 2Health News:FDA's Current Ability to Regulate Genetic Testing is Problematic, FDLI-AAAS Colloquium Attendees Say 2Health News:FDA's Current Ability to Regulate Genetic Testing is Problematic, FDLI-AAAS Colloquium Attendees Say 3
Used during the performance of balloon dilation procedures to inflate and deflate the balloon and measure the pressure within the balloon during the procedure. Supplied sterile in peel-open packages....
... Diameter; 5.4 Fr Straight Channel; 33 or ... MRO-7 Integral Operating Ureteroscopes offer a small ... easy access to the ureter for diagnosis ... Fr) is ideal for large operating instruments, ...
Semi-Rigid Ureteroscope...
... ACMI DUR-8 Elite's 8.7 Fr shaft reaches ... comparable scope providing complete intrarenal access, ... smooth, lubricious outer covering and working channel ... And its patented torque-stable shaft construction, tight-bend ...
Medicine Products: